Insulet (NASDAQ:PODD) Raised to Buy at Wall Street Zen

Insulet (NASDAQ:PODD) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

PODD has been the subject of a number of other research reports. Wells Fargo & Company lifted their target price on Insulet from $144.00 to $172.00 and gave the company an “equal weight” rating in a report on Thursday. UBS Group increased their price target on shares of Insulet from $150.00 to $171.00 and gave the stock a “neutral” rating in a report on Thursday. Robert W. Baird set a $175.00 price objective on shares of Insulet in a research report on Thursday, August 6th. Barclays boosted their price objective on shares of Insulet from $150.00 to $165.00 and gave the company an “equal weight” rating in a research note on Friday. Finally, Leerink Partners boosted their price objective on shares of Insulet from $143.00 to $167.00 and gave the company a “market perform” rating in a research note on Thursday. Twelve research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Insulet currently has a consensus rating of “Hold” and a consensus price target of $185.38.

Insulet Price Performance

Shares of NASDAQ PODD opened at $146.51 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51. Insulet has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The stock has a market cap of $10.16 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 1.12 and a beta of 1.06. The stock has a fifty day moving average of $141.97 and a 200-day moving average of $176.65.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. The business had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The firm’s quarterly revenue was up 19.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.24 EPS. Equities research analysts anticipate that Insulet will post 6.75 earnings per share for the current year.

Institutional Investors Weigh In On Insulet

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in shares of Insulet during the second quarter worth about $1,018,582,000. Arrowstreet Capital Limited Partnership increased its position in shares of Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after purchasing an additional 1,011,369 shares during the last quarter. Man Group plc purchased a new stake in Insulet in the second quarter valued at approximately $78,746,000. Amundi raised its stake in Insulet by 13.6% in the second quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock valued at $77,320,000 after purchasing an additional 60,929 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in Insulet in the second quarter valued at approximately $64,921,000.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

About Insulet

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps.

Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Insulet serves customers in the United States and international markets.